Skip to main content

Table 1 Baseline Characteristics

From: Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy

  Pre NLR < 3 (N = 19) Pre NLR ≥ 3 (N = 23) All (N = 42) p-value
Median, Age – median (range) 61 (45-85) 61 (24-82) 61 (24-85) 0.859
 Race– no. (%)     0.339
 Caucasian 14 (74) 16 (70) 30 (71)  
 African-American 5 (26) 4 (17) 9 (21)  
 Asian 0 (0) 3 (13) 3 (7)  
 Histology– no. (%)     0.330
 Clear Cell 17 (89) 16 (70) 33 (79)  
 Non-Clear cell 2 (11) 9 (30) 9 (21)  
Smoking Status– no. (%)     >0.99
 No 10 (53) 11 (48) 21 (50)  
 Yes 9 (47) 12 (52) 21 (50)  
Number of Prior anti-VEGF Therapies– no. (%)     0.093
 ≤1 16 (84) 13 (57) 29 (69)  
 > 1 3 (16) 10 (43) 13 (31)  
Duration of prior anti-VEGF Therapies– no. (%)     >0.99
 < 6 Months 8 (42) 10 (43) 18 (43)  
 ≥ 6 Months 11 (58) 13 (57) 24 (57)  
NLR at Day 15– no. (%)     <0.001
 < 3 15 (79) 2 (9) 17 (40)  
 ≥ 3 4 (21) 20 (87) 24 (57)  
NLR at Cycle 3– no. (%)a     0.001
 < 3 13 (68) 3 (13) 16 (38)  
 ≥ 3 4 (21) 16 (70) 20 (48)  
Types of anti-VEGF Therapies – no. (%)     
 Pazopanib 10 (34) 10 (77) 20 (48) 0.019
 Sunitinib 6 (21) 9 (69) 15 (36) 0.005
 Axitinib 0 (0) 9 (69) 9 (21) <0.001
 Sorafenib 0 (0) 6 (46) 6 (14) <0.001
 Bevacizumab 2 (7) 5 (38) 7 (17) 0.021
 Everolimus 2 (7) 5 (38) 7 (17) 0.021
 IL2 10 (34) 10 (77) 20 (48) 0.019
Histology – no. (%)     0.330
 Clear 17 (89) 16 (70) 33 (79)  
 Clear Cell W/ Sarcamatoid Features 0 (0) 3 (13) 3 (7)  
 Clear Cell W/ Papillary Features 2 (1) 3 (13) 5 (12)  
 Medullary 0 (0) 1 (4) 1 (2)  
Heng Prognostic Score– no. (%)     0.509
 Low 4 (21) 8 (35) 12 (29)  
 Intermediate 10 (53) 12 (52) 22 (52)  
 High 5 (26) 3 (13) 8 (19)  
MSKCC Prognostic Score– no. (%)     0.317
 Low 4 (21) 9 (39) 13 (31)  
 Intermediate 15 (79) 14 (61) 29 (69)  
Type of Immune Checkpoint Inhibitor Therapy– no. (%)     0.220
 Nivolumab 19 (66) 10 (77) 29 (69)  
 Nivolumab plus Nexavar 0 (0) 1 (8) 1 (2)  
 Nivolumab plus Votrient 1 (3) 2 (15) 3 (7)  
 Nivolumab + Ipilimumab 1 (3) 0 (0) 1 (2)  
 Ipilimumab 0 (0) 0 (0) 0 (0)  
 Avelumab 1 (3) 0 (0) 1 (2)  
 Pembrolizumab and Axitinib 5 (17) 0 (0) 5 (12)  
 Atezolizumab and Avastin 2 (7) 0 (0) 2 (5)  
  1. aData are not available for 6 patients